UCART 19

Drug Profile

UCART 19

Alternative Names: CD19CAR/RQR8+_TCRαβ–_T-cells; UCART19

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 12 Dec 2017 Preliminary safety and efficacy data from the phase I CALM and PALL trial in Acute lymphoblastic leukaemia presented at the 59th Annual Meeting of the American Association of Haematology (ASH-2017)
  • 27 Jul 2017 Cellectis and MolMed agree to develop and produce allogeneic CAR-T products for Cancer
  • 29 Jun 2017 Servier in-licenses viral vectorization technology from Transgene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top